The Investor
26 Aug 2026, 16:03
Eli Lilly Highlights Zepbound Healthcare Cost Savings in Older Adults
Eli Lilly (NYSE: LLY) released new real-world evidence showing that sustained use of its obesity drug Zepbound (tirzepatide) was associated with substantially lower healthcare costs among adults over age 55 with obesity or overweight.
The study found that patients remaining on Zepbound had lower rates of hospital admissions and emergency department visits than comparable untreated patients, with estimated healthcare savings increasing as treatment continued.
Healthcare Savings Increase Over Time
At six months, healthcare costs were as much as 15% lower for patients treated with Zepbound, representing savings of up to $181 per patient per month.
By 12 months, the difference widened substantially. Depending on the analytical method used, estimated savings ranged from $319 to $607 per patient per month, equivalent to approximately 25%-38% lower healthcare costs.
The study also found lower hospital admission and emergency department utilization across follow-up periods among Zepbound-treated patients in the primary analysis.
Findings Could Strengthen Zepbound's Economic Case
The results are potentially important for Lilly because they address one of the central questions surrounding widespread GLP-1 obesity treatment: whether the relatively high cost of medication can eventually be offset by reductions in other healthcare spending.
Lilly noted that estimated healthcare savings beginning at six months nearly covered the $195 monthly treatment cost under Medicare's GLP-1 Bridge program. By 12 months, estimated savings exceeded that monthly treatment cost.
That could strengthen the economic argument for broader payer and Medicare coverage of obesity medications, potentially supporting long-term adoption of Zepbound.
Important Limitation
The findings require some caution. This was a retrospective observational study rather than a randomized clinical trial. It included 15,843 adults over age 55, with Zepbound users matched with similar people who did not initiate a GLP-1 or GIP/GLP-1 treatment.
More importantly, the reported healthcare costs excluded the actual cost of Zepbound because claims data did not capture its net price. Therefore, the study demonstrates potential savings elsewhere in the healthcare system rather than proving that Zepbound reduces total healthcare spending after the drug's cost is included.
For Lilly, however, the study provides potentially valuable real-world evidence supporting Zepbound's broader economic benefits beyond weight loss. If similar findings are confirmed over longer periods, they could strengthen Lilly's case with insurers, employers and government programs for expanded obesity-drug coverage.
Eli Lilly (NYSE: LLY) released new real-world evidence showing that sustained use of its obesity drug Zepbound (tirzepatide) was associated with substantially lower healthcare costs among adults over age 55 with obesity or overweight.
The study found that patients remaining on Zepbound had lower rates of hospital admissions and emergency department visits than comparable untreated patients, with estimated healthcare savings increasing as treatment continued.
Healthcare Savings Increase Over Time
At six months, healthcare costs were as much as 15% lower for patients treated with Zepbound, representing savings of up to $181 per patient per month.
By 12 months, the difference widened substantially. Depending on the analytical method used, estimated savings ranged from $319 to $607 per patient per month, equivalent to approximately 25%-38% lower healthcare costs.
The study also found lower hospital admission and emergency department utilization across follow-up periods among Zepbound-treated patients in the primary analysis.
Findings Could Strengthen Zepbound's Economic Case
The results are potentially important for Lilly because they address one of the central questions surrounding widespread GLP-1 obesity treatment: whether the relatively high cost of medication can eventually be offset by reductions in other healthcare spending.
Lilly noted that estimated healthcare savings beginning at six months nearly covered the $195 monthly treatment cost under Medicare's GLP-1 Bridge program. By 12 months, estimated savings exceeded that monthly treatment cost.
That could strengthen the economic argument for broader payer and Medicare coverage of obesity medications, potentially supporting long-term adoption of Zepbound.
Important Limitation
The findings require some caution. This was a retrospective observational study rather than a randomized clinical trial. It included 15,843 adults over age 55, with Zepbound users matched with similar people who did not initiate a GLP-1 or GIP/GLP-1 treatment.
More importantly, the reported healthcare costs excluded the actual cost of Zepbound because claims data did not capture its net price. Therefore, the study demonstrates potential savings elsewhere in the healthcare system rather than proving that Zepbound reduces total healthcare spending after the drug's cost is included.
For Lilly, however, the study provides potentially valuable real-world evidence supporting Zepbound's broader economic benefits beyond weight loss. If similar findings are confirmed over longer periods, they could strengthen Lilly's case with insurers, employers and government programs for expanded obesity-drug coverage.
